Concomitant radiation therapy and chemotherapy in the treatment of advanced squamous carcinoma of the lower female genital tract

Gynecol Oncol. 1989 Aug;34(2):183-6. doi: 10.1016/0090-8258(89)90138-8.

Abstract

Twenty-three consecutive patients with advanced squamous carcinoma of the lower female genital tract were entered into a pilot study to determine the response rate and toxicity of a combination of intravenous cisplatin and 5-fluorouracil given concomitantly with radiation therapy. Twenty (87%) of the patients had a complete clinical response. Two patients (9%) had a partial response and one (4%) had stable disease. Nine (45%) of the complete responders have recurred with a median time to recurrence of 4 months. Seven (35%) had some component of local recurrence. The complete responders who have not recurred have been followed a median of 17 months. The acute toxicity was generally mild and there was no life-threatening acute complications. Three patients developed significant late complications. The response rate in this study was very high. The responses were usually prompt and dramatic, but often not sustained.

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Brachytherapy
  • Carcinoma, Squamous Cell / drug therapy
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / radiotherapy*
  • Cisplatin / administration & dosage
  • Combined Modality Therapy
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Neoplasm Staging
  • Radiotherapy Dosage
  • Uterine Cervical Neoplasms / drug therapy
  • Uterine Cervical Neoplasms / pathology
  • Uterine Cervical Neoplasms / radiotherapy*
  • Vaginal Neoplasms / drug therapy
  • Vaginal Neoplasms / pathology
  • Vaginal Neoplasms / radiotherapy*
  • Vulvar Neoplasms / drug therapy
  • Vulvar Neoplasms / pathology
  • Vulvar Neoplasms / radiotherapy

Substances

  • Cisplatin
  • Fluorouracil